Status: Recruiting
Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
Lubiprostone has established efficacy and a favorable safety profile in chronic constipation and irritable bowel syndrome with constipation (IBS-C). However, clinical data specifically supporting its use in slow-transit constipation (STC), a distinct subtype of chronic constipation, remains limited.
Participants needed: 346
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Third Military Medical UniversityUpdated: Jan 20, 2026Locations: 15
Eligibility criteria
Patients voluntarily participated in the study and provided signed informed cons... [+6]
Pregnant or lactating women. [+14]